Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study

We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication. A prospective observational study design of biochemical and clinical factor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2019-09, Vol.14 (9), p.e0210674
Hauptverfasser: Mitchell, Alex J, Vancampfort, Davy, Manu, Peter, Correll, Christoph U, Wampers, Martien, van Winkel, Ruud, Yu, Weiping, De Hert, Marc
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page e0210674
container_title PloS one
container_volume 14
creator Mitchell, Alex J
Vancampfort, Davy
Manu, Peter
Correll, Christoph U
Wampers, Martien
van Winkel, Ruud
Yu, Weiping
De Hert, Marc
description We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication. A prospective observational study design of biochemical and clinical factors was used. Biochemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing (OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients receiving antipsychotics. Clinical variables were gender, age, global assessment of functioning (GAF), mental health clinicians' global impression (CGI), duration of severe mental illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using combined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Diabetes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose (IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at conventional cut-offs. Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new criteria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p = 0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT, IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and 75% of people with diabetes, respectively. The conventional HBA1c cut-point of ≥6.5% (48 mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of ≥5.7% improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered reasonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accuracy namely: BMI, waist/hip ratio and height. A BMI < 30 had a 92% negative predictive value in ruling-out diabetes. Of those not diabetic, 20% had a BMI ≥ 30. However, for complete diagnosis a specific biochemical protocol is still necessary. Patients with SMI maintained on antipsychotic medication cannot be reliably screened for diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm consisting of HBA1c ≥5.7% followed by both FG and OGTT which does not require all patients to have OGTT and FG.
doi_str_mv 10.1371/journal.pone.0210674
format Article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2289570412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A599263193</galeid><doaj_id>oai_doaj_org_article_3d0c41d9f4a840b1b181ce5338665303</doaj_id><sourcerecordid>A599263193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-f7bc44ec7403b53d55cb3d6ace95fec62103108b0f7552b61344e0c8c53265a73</originalsourceid><addsrcrecordid>eNqNk9tq3DAQhk1padK0b1BaQaHQi91KluXDTUsIPQQCgR4vhSyP11q01lYjp82T9fU6u9mEXWih-MLW6Jt_5F8zWfZU8LmQlXi9DFMcjZ-vwwhzngteVsW97Fg0Mp-VOZf3976PskeIS86VrMvyYXYkhRJSNfVx9vv74OzArHejs8YzM3asdcEOsNqu1xE6Z1OIyHAIk6ddYBNCx1JgaCPAyPoQWedMCwmQuZGtTXIwJmQ_XRoYQnRhQraiEAk670dAZBEsuCs3Lqhkcmu8tkNIzhJG9UggjG_ZKfMmLoCFlkSutkFSwDR114-zB73xCE9275Ps6_t3X84-zi4uP5yfnV7MbNnkadZXrS0KsFXBZatkp5RtZVcaC43qwZZkmxS8bnlfKZW3pZBEc1tbJfNSmUqeZM9vdNc-oN55jjrP60ZVvBA5Eec3RBfMUq-jW5l4rYNxehsIcaFNpD_zoGXHbSG6pi9MXfBWtKIWFpTc3IqSXJLWm121qSUjLFkWjT8QPdwZ3aAX4UrT3eeFqkngxU4ghh8TYPrHkXfUwtCp3NgHErMrh1afqqbJS0mdQ9T8LxQ93aY3qOt6R_GDhFcHCcQk-JUWZkLU558__T97-e2QfbnHDmB8GjD4adMPeAgWN6CNATFCf-ec4HozNLdu6M3Q6N3QUNqzfdfvkm6nRP4B-10WCg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289570412</pqid></control><display><type>article</type><title>Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Mitchell, Alex J ; Vancampfort, Davy ; Manu, Peter ; Correll, Christoph U ; Wampers, Martien ; van Winkel, Ruud ; Yu, Weiping ; De Hert, Marc</creator><contributor>McKenna, Peter John</contributor><creatorcontrib>Mitchell, Alex J ; Vancampfort, Davy ; Manu, Peter ; Correll, Christoph U ; Wampers, Martien ; van Winkel, Ruud ; Yu, Weiping ; De Hert, Marc ; McKenna, Peter John</creatorcontrib><description>We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication. A prospective observational study design of biochemical and clinical factors was used. Biochemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing (OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients receiving antipsychotics. Clinical variables were gender, age, global assessment of functioning (GAF), mental health clinicians' global impression (CGI), duration of severe mental illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using combined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Diabetes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose (IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at conventional cut-offs. Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new criteria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p = 0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT, IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and 75% of people with diabetes, respectively. The conventional HBA1c cut-point of ≥6.5% (48 mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of ≥5.7% improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered reasonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accuracy namely: BMI, waist/hip ratio and height. A BMI &lt; 30 had a 92% negative predictive value in ruling-out diabetes. Of those not diabetic, 20% had a BMI ≥ 30. However, for complete diagnosis a specific biochemical protocol is still necessary. Patients with SMI maintained on antipsychotic medication cannot be reliably screened for diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm consisting of HBA1c ≥5.7% followed by both FG and OGTT which does not require all patients to have OGTT and FG.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0210674</identifier><identifier>PMID: 31513598</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Algorithms ; Antipsychotic agents ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Biochemistry ; Biology and life sciences ; Biomarkers ; Criteria ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - diagnosis ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - etiology ; Diabetes Mellitus - metabolism ; Diabetics ; Diagnosis ; Drug therapy ; Drugs ; Fasting ; Female ; Glucose ; Glucose - metabolism ; Glucose tolerance ; Glucose tolerance test ; Glycosylated hemoglobin ; Health ; Health risks ; Health screening ; Hemoglobin ; Hemoglobins ; Hip ; Hospital patients ; Humans ; Insulin ; Insulin resistance ; Laboratory testing ; Lipids ; Male ; Medical diagnosis ; Medicine and Health Sciences ; Mental disorders ; Mental Disorders - complications ; Mental Disorders - drug therapy ; Mental health ; Mentally ill persons ; Middle Aged ; Mortality ; Observational studies ; Phenotype ; Prevalence ; Prospective Studies ; Psychotropic drugs ; Reproducibility of Results ; Risk ; Risk assessment ; Risk factors ; ROC Curve ; Sensitivity and Specificity ; Systematic review ; Type 2 diabetes</subject><ispartof>PloS one, 2019-09, Vol.14 (9), p.e0210674</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><rights>2019 Mitchell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Mitchell et al 2019 Mitchell et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-f7bc44ec7403b53d55cb3d6ace95fec62103108b0f7552b61344e0c8c53265a73</citedby><cites>FETCH-LOGICAL-c692t-f7bc44ec7403b53d55cb3d6ace95fec62103108b0f7552b61344e0c8c53265a73</cites><orcidid>0000-0001-6014-598X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742458/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742458/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31513598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>McKenna, Peter John</contributor><creatorcontrib>Mitchell, Alex J</creatorcontrib><creatorcontrib>Vancampfort, Davy</creatorcontrib><creatorcontrib>Manu, Peter</creatorcontrib><creatorcontrib>Correll, Christoph U</creatorcontrib><creatorcontrib>Wampers, Martien</creatorcontrib><creatorcontrib>van Winkel, Ruud</creatorcontrib><creatorcontrib>Yu, Weiping</creatorcontrib><creatorcontrib>De Hert, Marc</creatorcontrib><title>Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication. A prospective observational study design of biochemical and clinical factors was used. Biochemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing (OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients receiving antipsychotics. Clinical variables were gender, age, global assessment of functioning (GAF), mental health clinicians' global impression (CGI), duration of severe mental illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using combined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Diabetes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose (IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at conventional cut-offs. Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new criteria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p = 0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT, IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and 75% of people with diabetes, respectively. The conventional HBA1c cut-point of ≥6.5% (48 mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of ≥5.7% improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered reasonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accuracy namely: BMI, waist/hip ratio and height. A BMI &lt; 30 had a 92% negative predictive value in ruling-out diabetes. Of those not diabetic, 20% had a BMI ≥ 30. However, for complete diagnosis a specific biochemical protocol is still necessary. Patients with SMI maintained on antipsychotic medication cannot be reliably screened for diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm consisting of HBA1c ≥5.7% followed by both FG and OGTT which does not require all patients to have OGTT and FG.</description><subject>Adult</subject><subject>Algorithms</subject><subject>Antipsychotic agents</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Biochemistry</subject><subject>Biology and life sciences</subject><subject>Biomarkers</subject><subject>Criteria</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - diagnosis</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diabetes Mellitus - etiology</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Diabetics</subject><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Fasting</subject><subject>Female</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Glucose tolerance</subject><subject>Glucose tolerance test</subject><subject>Glycosylated hemoglobin</subject><subject>Health</subject><subject>Health risks</subject><subject>Health screening</subject><subject>Hemoglobin</subject><subject>Hemoglobins</subject><subject>Hip</subject><subject>Hospital patients</subject><subject>Humans</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Laboratory testing</subject><subject>Lipids</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medicine and Health Sciences</subject><subject>Mental disorders</subject><subject>Mental Disorders - complications</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental health</subject><subject>Mentally ill persons</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Phenotype</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Psychotropic drugs</subject><subject>Reproducibility of Results</subject><subject>Risk</subject><subject>Risk assessment</subject><subject>Risk factors</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><subject>Systematic review</subject><subject>Type 2 diabetes</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tq3DAQhk1padK0b1BaQaHQi91KluXDTUsIPQQCgR4vhSyP11q01lYjp82T9fU6u9mEXWih-MLW6Jt_5F8zWfZU8LmQlXi9DFMcjZ-vwwhzngteVsW97Fg0Mp-VOZf3976PskeIS86VrMvyYXYkhRJSNfVx9vv74OzArHejs8YzM3asdcEOsNqu1xE6Z1OIyHAIk6ddYBNCx1JgaCPAyPoQWedMCwmQuZGtTXIwJmQ_XRoYQnRhQraiEAk670dAZBEsuCs3Lqhkcmu8tkNIzhJG9UggjG_ZKfMmLoCFlkSutkFSwDR114-zB73xCE9275Ps6_t3X84-zi4uP5yfnV7MbNnkadZXrS0KsFXBZatkp5RtZVcaC43qwZZkmxS8bnlfKZW3pZBEc1tbJfNSmUqeZM9vdNc-oN55jjrP60ZVvBA5Eec3RBfMUq-jW5l4rYNxehsIcaFNpD_zoGXHbSG6pi9MXfBWtKIWFpTc3IqSXJLWm121qSUjLFkWjT8QPdwZ3aAX4UrT3eeFqkngxU4ghh8TYPrHkXfUwtCp3NgHErMrh1afqqbJS0mdQ9T8LxQ93aY3qOt6R_GDhFcHCcQk-JUWZkLU558__T97-e2QfbnHDmB8GjD4adMPeAgWN6CNATFCf-ec4HozNLdu6M3Q6N3QUNqzfdfvkm6nRP4B-10WCg</recordid><startdate>20190912</startdate><enddate>20190912</enddate><creator>Mitchell, Alex J</creator><creator>Vancampfort, Davy</creator><creator>Manu, Peter</creator><creator>Correll, Christoph U</creator><creator>Wampers, Martien</creator><creator>van Winkel, Ruud</creator><creator>Yu, Weiping</creator><creator>De Hert, Marc</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6014-598X</orcidid></search><sort><creationdate>20190912</creationdate><title>Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study</title><author>Mitchell, Alex J ; Vancampfort, Davy ; Manu, Peter ; Correll, Christoph U ; Wampers, Martien ; van Winkel, Ruud ; Yu, Weiping ; De Hert, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-f7bc44ec7403b53d55cb3d6ace95fec62103108b0f7552b61344e0c8c53265a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Algorithms</topic><topic>Antipsychotic agents</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Biochemistry</topic><topic>Biology and life sciences</topic><topic>Biomarkers</topic><topic>Criteria</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - diagnosis</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diabetes Mellitus - etiology</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Diabetics</topic><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Fasting</topic><topic>Female</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Glucose tolerance</topic><topic>Glucose tolerance test</topic><topic>Glycosylated hemoglobin</topic><topic>Health</topic><topic>Health risks</topic><topic>Health screening</topic><topic>Hemoglobin</topic><topic>Hemoglobins</topic><topic>Hip</topic><topic>Hospital patients</topic><topic>Humans</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Laboratory testing</topic><topic>Lipids</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medicine and Health Sciences</topic><topic>Mental disorders</topic><topic>Mental Disorders - complications</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental health</topic><topic>Mentally ill persons</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Phenotype</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Psychotropic drugs</topic><topic>Reproducibility of Results</topic><topic>Risk</topic><topic>Risk assessment</topic><topic>Risk factors</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><topic>Systematic review</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mitchell, Alex J</creatorcontrib><creatorcontrib>Vancampfort, Davy</creatorcontrib><creatorcontrib>Manu, Peter</creatorcontrib><creatorcontrib>Correll, Christoph U</creatorcontrib><creatorcontrib>Wampers, Martien</creatorcontrib><creatorcontrib>van Winkel, Ruud</creatorcontrib><creatorcontrib>Yu, Weiping</creatorcontrib><creatorcontrib>De Hert, Marc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mitchell, Alex J</au><au>Vancampfort, Davy</au><au>Manu, Peter</au><au>Correll, Christoph U</au><au>Wampers, Martien</au><au>van Winkel, Ruud</au><au>Yu, Weiping</au><au>De Hert, Marc</au><au>McKenna, Peter John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2019-09-12</date><risdate>2019</risdate><volume>14</volume><issue>9</issue><spage>e0210674</spage><pages>e0210674-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication. A prospective observational study design of biochemical and clinical factors was used. Biochemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing (OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients receiving antipsychotics. Clinical variables were gender, age, global assessment of functioning (GAF), mental health clinicians' global impression (CGI), duration of severe mental illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using combined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Diabetes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose (IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at conventional cut-offs. Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new criteria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p = 0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT, IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and 75% of people with diabetes, respectively. The conventional HBA1c cut-point of ≥6.5% (48 mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of ≥5.7% improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered reasonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accuracy namely: BMI, waist/hip ratio and height. A BMI &lt; 30 had a 92% negative predictive value in ruling-out diabetes. Of those not diabetic, 20% had a BMI ≥ 30. However, for complete diagnosis a specific biochemical protocol is still necessary. Patients with SMI maintained on antipsychotic medication cannot be reliably screened for diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm consisting of HBA1c ≥5.7% followed by both FG and OGTT which does not require all patients to have OGTT and FG.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31513598</pmid><doi>10.1371/journal.pone.0210674</doi><tpages>e0210674</tpages><orcidid>https://orcid.org/0000-0001-6014-598X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2019-09, Vol.14 (9), p.e0210674
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2289570412
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry
subjects Adult
Algorithms
Antipsychotic agents
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Antipsychotics
Biochemistry
Biology and life sciences
Biomarkers
Criteria
Diabetes
Diabetes mellitus
Diabetes Mellitus - diagnosis
Diabetes Mellitus - epidemiology
Diabetes Mellitus - etiology
Diabetes Mellitus - metabolism
Diabetics
Diagnosis
Drug therapy
Drugs
Fasting
Female
Glucose
Glucose - metabolism
Glucose tolerance
Glucose tolerance test
Glycosylated hemoglobin
Health
Health risks
Health screening
Hemoglobin
Hemoglobins
Hip
Hospital patients
Humans
Insulin
Insulin resistance
Laboratory testing
Lipids
Male
Medical diagnosis
Medicine and Health Sciences
Mental disorders
Mental Disorders - complications
Mental Disorders - drug therapy
Mental health
Mentally ill persons
Middle Aged
Mortality
Observational studies
Phenotype
Prevalence
Prospective Studies
Psychotropic drugs
Reproducibility of Results
Risk
Risk assessment
Risk factors
ROC Curve
Sensitivity and Specificity
Systematic review
Type 2 diabetes
title Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A27%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Which%20clinical%20and%20biochemical%20predictors%20should%20be%20used%20to%20screen%20for%20diabetes%20in%20patients%20with%20serious%20mental%20illness%20receiving%20antipsychotic%20medication?%20A%20large%20observational%20study&rft.jtitle=PloS%20one&rft.au=Mitchell,%20Alex%20J&rft.date=2019-09-12&rft.volume=14&rft.issue=9&rft.spage=e0210674&rft.pages=e0210674-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0210674&rft_dat=%3Cgale_plos_%3EA599263193%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2289570412&rft_id=info:pmid/31513598&rft_galeid=A599263193&rft_doaj_id=oai_doaj_org_article_3d0c41d9f4a840b1b181ce5338665303&rfr_iscdi=true